{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:10:59Z","timestamp":1794543059654,"version":"4.9.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40265-025-02178-w","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:30:11Z","timestamp":1746405011000},"page":"845-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Suzetrigine: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"2178_CR1","unstructured":"US Food & Drug Administration. FDA approves novel non-opioid treatment for moderate to severe acute pain [media release]. 30 Jan 2025. https:\/\/www.fda.gov\/."},{"issue":"11","key":"2178_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11916-024-01295-7","volume":"28","author":"AD Kaye","year":"2024","unstructured":"Kaye AD, Everett ES, Lehuquet AM, et al. Frontiers in acute pain management: emerging concepts in pain pathways and the role of VX-548 as a novel NaV1.8 inhibitor: a narrative review. Curr Pain Headache Rep. 2024;28(11):1135\u201343.","journal-title":"Curr Pain Headache Rep"},{"issue":"9","key":"2178_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s11916-024-01265-z","volume":"28","author":"AD Kaye","year":"2024","unstructured":"Kaye AD, Greene DR, Nguyen C, et al. Emerging medications and strategies in acute pain management: evolving role of novel sodium and calcium channel blockers, peptide-based pharmacologic drugs, and non-medicinal methods. Curr Pain Headache Rep. 2024;28(9):853\u201362.","journal-title":"Curr Pain Headache Rep"},{"issue":"5","key":"2178_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJMe2305708","volume":"389","author":"EG Phimister","year":"2023","unstructured":"Phimister EG, Waxman SG. Targeting a peripheral sodium channel to treat pain. N Engl J Med. 2023;389(5):466\u20139.","journal-title":"N Engl J Med"},{"key":"2178_CR5","unstructured":"Vertex Pharmaceuticals Inc. Suzetrigine (VX-548) ASA update. 2024. https:\/\/investors.vrtx.com\/. Accessed 20 Feb 2025."},{"key":"2178_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00697-0","author":"JD Osteen","year":"2025","unstructured":"Osteen JD, Immani S, Tapley TL, et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025. https:\/\/doi.org\/10.1007\/s40122-024-00697-0.","journal-title":"Pain Ther"},{"key":"2178_CR7","unstructured":"Vertex Pharmaceuticals Inc. Vertex announces FDA approval of JOURNAVXTM (suzetrigine), a first-in-class treatment for adults with moderate to severe acute pain [media release]. 30 Jan 2025. https:\/\/news.vrtx.com\/."},{"key":"2178_CR8","unstructured":"Vertex Pharmaceuticals Inc. Suzetrigine: US prescribing information. 2025. https:\/\/www.journavx.com\/. Accessed 20 Feb 2025."},{"key":"2178_CR9","doi-asserted-by":"publisher","first-page":"102538","DOI":"10.1016\/j.cbpa.2024.102538","volume":"83","author":"H Wang","year":"2024","unstructured":"Wang H, Huang J, Zang J, et al. Drug discovery targeting NaV1.8: structural insights and therapeutic potential. Curr Opin Chem Biol. 2024;83:102538.","journal-title":"Curr Opin Chem Biol"},{"issue":"5","key":"2178_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2209870","volume":"389","author":"J Jones","year":"2023","unstructured":"Jones J, Correll DJ, Lechner SM, et al. Selective inhibition of NaV1.8 with VX-548 for acute pain. N Engl J Med. 2023;389(5):393\u2013405.","journal-title":"N Engl J Med"},{"key":"2178_CR11","unstructured":"Vertex Pharmaceuticals Inc. VX-548 phase 2 results in painful diabetic neuropathy. 2023. https:\/\/investors.vrtx.com\/. Accessed 17 Feb 2025."},{"key":"2178_CR12","unstructured":"Vertex Pharmaceuticals Inc. Suzetrigine (VX-548) phase 2 results in painful lumbosacral radiculopathy. 2024. https:\/\/investors.vrtx.com\/. Accessed 20 Feb 2025."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02178-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:03:32Z","timestamp":1747998212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02178-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2178"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02178-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"19 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}